Moving the Needle on Alzheimer's Disease with an Anti-Oligomer Antibody
- PMID: 36599066
- PMCID: PMC12085230
- DOI: 10.1056/NEJMe2214981
Moving the Needle on Alzheimer's Disease with an Anti-Oligomer Antibody
Comment on
-
Lecanemab in Early Alzheimer's Disease.N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29. N Engl J Med. 2023. PMID: 36449413 Clinical Trial.
References
-
- van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer’s disease. N Engl J Med 2023; 388: 9–21. - PubMed
-
- Nilsberth C, Westlind-Danielsson A, Eckman CB, et al. The ‘Arctic’ APP mutation (E693G) causes Alzheimer’s disease by enhanced Abeta protofibril formation. Nat Neurosci 2001; 4: 887–93. - PubMed
-
- Päiviö A, Jarvet J, Gräslund A, Lannfelt L, Westlind-Danielsson A. Unique physicochemical profile of beta-amyloid peptide variant Abeta1-40E22G protofibrils: conceivable neuropathogen in Arctic mutant carriers. J Mol Biol 2004; 339: 145–59. - PubMed
-
- Levy E, Carman MD, Fernandez-Madrid IJ, et al. Mutation of the Alzheimer’s disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science 1990; 248: 1124–6. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical